[Form 4] CareDx, Inc. Insider Trading Activity

Rhea-AI Filing Summary

CareDx Director Peter Maag has reported the sale of 10,000 shares of common stock at a weighted average price of $19.242 per share on June 17, 2025. The transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 21, 2024.

The shares were sold in multiple transactions with prices ranging from $18.80 to $19.52. Following the reported transaction, Maag continues to hold 318,846 shares directly.

• Transaction Type: Sale (S)
• Ownership Type: Direct (D)
• Total Transaction Value: Approximately $192,420
• Trading Plan: Executed under pre-established 10b5-1 plan

This insider sale represents approximately 3% of Maag's direct holdings in CareDx and was conducted under a predetermined trading plan, which helps avoid concerns about insider trading.

Positive

• None.

Negative

• Director Peter Maag sold 10,000 shares at an average price of $19.24 through a pre-planned 10b5-1 trading plan, while retaining 318,846 shares

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maag Peter

(Last) (First) (Middle)

C/O CAREDX, INC.

8000 MARINA BOULEVARD

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CareDx, Inc. [ CDNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		S		10,000(1)	D	$19.242(2)	318,846	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $19.52, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

	/s/ Peter Maag	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CDNA shares did Peter Maag sell on June 17, 2025?

Peter Maag sold 10,000 shares of CareDx (CDNA) common stock on June 17, 2025, at a weighted average price of $19.242 per share.

What is Peter Maag's remaining CDNA stock position after the June 2025 sale?

Following the reported transaction, Peter Maag directly owns 318,846 shares of CareDx (CDNA) common stock.

Was CDNA insider Peter Maag's stock sale part of a 10b5-1 trading plan?

Yes, the transaction was executed pursuant to a Rule 10b5-1 trading plan that Peter Maag adopted on August 21, 2024.

What price range did Peter Maag sell his CDNA shares for in June 2025?

Peter Maag sold the shares at prices ranging from $18.80 to $19.52 per share, with a weighted average price of $19.242.

What is Peter Maag's role at CareDx (CDNA)?

According to the Form 4 filing, Peter Maag serves as a Director of CareDx (CDNA).